EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High Local and Systemic Expression of Pentraxin-3 in Anaplastic Thyroid Cancer

Andreea Bojoga iD, Pepijn van Houten iD, Martin Jaeger iD, Katrin Rabold, Birgitte Walgreen, Liesbeth van Emst, Dumitru Ioachim, Ilse van Engen-van Grunsven, Corin Badiu iD, Romana T Netea-Maier iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262311335 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Andreea Bojoga und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania. Hauptthemen laut MEDLINE: C-Reactive Protein, Serum Amyloid P-Component, Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Joint Programme for Rare Disease under Research mobility grant, Next Generation EU: Program of National Recovery and Resilience grant: Decoding the im-mune-inflammatory axis in rare non-medullary thyroid cancer as an innova…, the European Joint Programme for Rare Disease under Research mobility.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic inflammation plays a key role in cancer pathogenesis. Aggressive thyroid cancer is associated with immune infiltration and systemic inflammation. Long pentraxin 3 (PTX3) is an inflammatory protein implicated in tumor progression. This study evaluates PTX3 plasma levels in patients with non-medullary thyroid cancer (TC) compared to benign thyroid disease and investigates its tissue expression. We prospectively included 55 TC patients: 42 papillary, 3 follicular, 4 oncocytic, 4 anaplastic (ATC), and 2 poorly differentiated (PDTC). The control group consisted of 32 patients with benign thyroid disease. PTX3 plasma concentrations were measured by ELISA, and tissue expression of PTX3 and CD68 was analyzed using immunohistochemistry. PTX3 plasma levels did not significantly differ between TC and controls, but patients with PDTC and ATC had markedly higher concentrations. Tissue analysis showed strong PTX3 expression in three of four ATC cases in tumor and stromal cells, whereas benign and differentiated thyroid tissues exhibited minimal staining. CD68 expression was positive in ATC, indicating tumor-associated macrophage infiltration, but a few cells were double-positive for PTX3 and CD68. Our findings suggest a possible association between PTX3 and aggressive TC, particularly ATC. Further studies are needed to validate these findings and elucidate the cellular origin and functional role of PTX3.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

C-Reactive ProteinSerum Amyloid P-ComponentThyroid NeoplasmsThyroid Carcinoma, AnaplasticHumansMaleFemaleMiddle AgedAgedAdultAntigens, Differentiation, MyelomonocyticAntigens, CDBiomarkers, TumorImmunohistochemistryCD68 MoleculePentraxins

Stichwörter der Autor:innen

anaplastic thyroid cancernon-medullary thyroid cancerpentraxin 3tumor-associated inflammation

Substanzen

C-Reactive ProteinSerum Amyloid P-ComponentAntigens, Differentiation, MyelomonocyticAntigens, CDBiomarkers, TumorCD68 MoleculePentraxinsCD68 antigen, human

Autor:innen und Institutionen

  • Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
  • Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
  • Rheumatology Research Laboratory, Department of Internal Medicine, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
  • Department of Pathology, National Institute of Endocrinology C. I. Parhon, 011863 Bucharest, Romania.
  • Department of Pathology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
  • Department of Endocrinology IV, National Institute of Endocrinology C. I. Parhon, 011863 Bucharest, Romania.

ORCID-Profile: Andreea Bojoga, Pepijn van Houten, Martin Jaeger, Corin Badiu, Romana T Netea-Maier

Förderung

  • European Joint Programme for Rare Disease under Research mobility grant
  • Next Generation EU: Program of National Recovery and Resilience grant: Decoding the im-mune-inflammatory axis in rare non-medullary thyroid cancer as an innova…
  • the European Joint Programme for Rare Disease under Research mobility
  • the University of Medicine and Pharmacy Carol Davila

Zitieren

APA

Bojoga, A., van Houten, P., Jaeger, M., Rabold, K., Walgreen, B., van Emst, L., Ioachim, D., van Engen-van Grunsven, I., Badiu, C., & Netea-Maier, R. T. (2025). High Local and Systemic Expression of Pentraxin-3 in Anaplastic Thyroid Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262311335

Vancouver

Bojoga A, van Houten P, Jaeger M, Rabold K, Walgreen B, van Emst L, et al. High Local and Systemic Expression of Pentraxin-3 in Anaplastic Thyroid Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262311335

BibTeX
@article{Bojoga2025,
  author = {Bojoga, Andreea and van Houten, Pepijn and Jaeger, Martin and Rabold, Katrin and Walgreen, Birgitte and van Emst, Liesbeth and Ioachim, Dumitru and van Engen-van Grunsven, Ilse and Badiu, Corin and Netea-Maier, Romana T},
  title = {High Local and Systemic Expression of Pentraxin-3 in Anaplastic Thyroid Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262311335}
}
Kostenlos starten →